Stay updated with breaking news from Human Use. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Takeda (TAK) announced the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors for the treatment of adult patients with previously treated metastatic colorectal cancer or mCRC.
/PRNewswire/ -- Pierre Fabre Laboratories announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...
CHMP has voiced its support for the approval of fruquintinib in previously treated metastatic colorectal cancer.
Frontline amivantamab with chemotherapy has been recommended for approval by the CHMP in EGFR exon 20 insertion+ non–small cell lung cancer.
European Union marketing authorization recommended for Altuvoct for hemophilia A caused by factor VIII deficiency.